FDA Approved: EXEMESTANE — Supplemental Application (Upsher-Smith Laboratories, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Exemestane (Upsher-Smith Laboratories) under an ANDA, affecting a generic aromatase inhibitor used in breast can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)

Snippet

SUPPL AP for EXEMESTANE (EXEMESTANE)